Selective antagonist of Ca2+-permeable AMPA receptors; blocks AMPA receptors lacking the GluR2 subunit. Protects hippocampal neurons against global ischemia-induced cell death.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 479.91. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.08 mL||10.42 mL||20.84 mL|
|5 mM||0.42 mL||2.08 mL||4.17 mL|
|10 mM||0.21 mL||1.04 mL||2.08 mL|
|50 mM||0.04 mL||0.21 mL||0.42 mL|
References are publications that support the products' biological activity.
Tsubokawa et al (1995) Effects of spider toxin and its analogue on glutamate-activated currents in the hippocampal CA1 neuron after ischaemia. J.Neurophysiol. 74 218 PMID: 7472325
Koike et al (1997) Blocking effect of 1-naphthyl acetyl spermine on Ca2+-permeable AMPA receptors in cultured rat hippocampal neurons. Neurosci.Res. 29 27 PMID: 9293490
Nilsen and England (2007) A subtype-selective, use-dependent inhibitor of native AMPA receptors. J.Am.Chem.Soc. 129 4902 PMID: 17391037
If you know of a relevant reference for Naspm trihydrochloride, please let us know.
View Related Products by Product Action
Keywords: Naspm trihydrochloride, supplier, AMPA, receptors, antagonists, GluR2, calcium-permeable, Ca2+, ionotropic, glutamate, receptors, iGluR, 1-Naphthyl, acetyl, spermine, trihydrochloride, AMPA, Receptors, AMPA, Receptors, Tocris Bioscience
10 Citations for Naspm trihydrochloride
Citations are publications that use Tocris products. Selected citations for Naspm trihydrochloride include:
Park et al (2016) Calcium-Permeable AMPA Receptors Mediate the Induction of the Protein Kinase A-Dependent Component of Long-Term Potentiation in the Hippocampus. J Neurosci 36 622 PMID: 26758849
Megill et al (2015) Defective Age-Dependent Metaplasticity in a Mouse Model of Alzheimer's Disease. Nature 35 11346 PMID: 26269641
Jaafari et al (2012) PICK1 mediates transient synaptic expression of GluA2-lacking AMPA receptors during glycine-induced AMPA receptor trafficking. J Neurosci 32 11618 PMID: 22915106
Villers et al (2012) Long-lasting LTP requires neither repeated trains for its induction nor protein synthesis for its development. PLoS One 7 e40823 PMID: 22792408
Kim and Ziff (2014) Calcineurin mediates synaptic scaling via synaptic trafficking of Ca2+-permeable AMPA receptors. PLoS Biol 12 e1001900 PMID: 24983627
Fernandes et al (2014) In vitro ischemia triggers a transcriptional response to down-regulate synaptic proteins in hippocampal neurons. PLoS One 9 e99958 PMID: 24960035
Roy et al (2014) Enhancement of morphological plasticity in hippocampal neurons by a physically modified saline via phosphatidylinositol-3 kinase. J Neurosci 9 e101883 PMID: 25007337
Lee et al (2014) Synapse elimination and learning rules co-regulated by MHC class I H2-Db. J Cereb Blood Flow Metab 509 195 PMID: 24695230
Blanco-Suárez et al (2014) Differential Tiam1/Rac1 activation in hippocampal and cortical neurons mediates differential spine shrinkage in response to oxygen/glucose deprivation. Nat Commun 34 1898 PMID: 25248834
Cabañero et al (2013) Pain after discontinuation of morphine treatment is associated with synaptic increase of GluA4-containing AMPAR in the dorsal horn of the spinal cord. Neuropsychopharmacology 38 1472 PMID: 23403695
Do you know of a great paper that uses Naspm trihydrochloride from Tocris? If so please let us know.
Reviews for Naspm trihydrochloride
There are currently no reviews for this product. Be the first to review Naspm trihydrochloride and earn rewards!
Have you used Naspm trihydrochloride?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.